FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Nature Editorial Urges Academic Scientists to Help FDA

A Nature editorial says FDA needs help from academic scientists to review and approve new drug therapies because in-house talent is weak.

Medical Devices

FDA Clears Mauna Kea Confocal Miniprobes

FDA clears a Mauna Kea Technologies 510(k) for its CelioFlex UHD Confocal Miniprobes for use with the companys Cellvizio laser endomicroscopy platform...

Federal Register

48 ANDA Bioequivalence Guidances Published

Federal Register notice: FDA announces the availability of 48 final product-specific guidances that recommend the design of bioequivalence studies to ...

Federal Register

Oncologic Drugs Panel to Review Sutent sNDA

Federal Register notice: FDA announces a 9/19 Oncologic Drugs Advisory Committee meeting to review a C.P. Pharmaceuticals supplemental NDA for Sutent.

Human Drugs

Teva Gains Approval for new Qvar RediHaler

FDA approves a Teva Pharmaceutical Industries NDA for Qvar RediHaler (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler f...

Federal Register

Vaccines Panel to Review Glaxo Zoster Vaccine

Federal Register notice: FDA announces a 9/13 Vaccines and Related Biological Products Advisory Committee meeting that will review GlaxoSmithKline Bio...

Human Drugs

Vernalis Gets Complete Response on Rx Cough-Cold NDA

FDA issues Vernalis a complete response letter on its NDA for CCP-08, an undisclosed extended-release product being developed for Vernalis by Tris Pha...

Federal Register

Latest Federal Register Notices

FDA Review posts the Federal Register notices for the week ending 8/4/2017.

Human Drugs

Tentative OK for Perrigos Generic Skin Gel

FDA tentatively approves a Perrigo ANDA for a generic version of Galderma Labs Mirvaso (brimonidine) topical gel 0.33%, indicated for the topical trea...

Human Drugs

Lilly Plans 2018 NDA for Migraine Drug After Trial Results

Eli Lilly says its investigational migraine drug lasmiditan met its primary endpoint in SPARTAN, a second Phase 3 study of the therapy, and a 2018 NDA...